Nursing Elites

1. A 23-year-old pregnant female visits her primary care provider for her final prenatal checkup. The primary care provider determines that the fetus has developed an infection in utero. Which of the following would be increased in the fetus at birth?

• A. IgG
• B. IgA
• C. IgM
• D. IgD

Correct answer: C

Rationale: The correct answer is IgM. IgM is the first antibody produced in response to an infection and is elevated in a fetus with an in utero infection. IgG is the primary antibody responsible for providing immunity to the fetus and is transferred across the placenta during the third trimester. IgA is mainly found in mucosal areas and colostrum but not significantly elevated in fetal infections. IgD is involved in the development and maturation of B cells but not typically increased in fetal infections.

2. A nurse is administering testosterone to a patient with hypogonadism. What outcome indicates that the treatment is having the desired effect?

• A. Increased libido
• B. Increased muscle mass
• C. Improved secondary sexual characteristics
• D. Decreased sperm count

Correct answer: C

Rationale: The correct answer is C: 'Improved secondary sexual characteristics.' Testosterone therapy in patients with hypogonadism typically leads to improved secondary sexual characteristics, which include increased muscle mass and libido. While increased libido (choice A) and increased muscle mass (choice B) are effects of testosterone therapy, they are more specific outcomes related to secondary sexual characteristics. Decreased sperm count (choice D) would not be an expected outcome of testosterone therapy for hypogonadism, as testosterone is essential for sperm production.

3. A nurse is teaching a patient about the use of raloxifene (Evista) for the prevention of osteoporosis. What is the primary therapeutic action of this medication?

• A. It decreases the absorption of calcium from the intestines.
• B. It decreases bone resorption and increases bone density.
• C. It increases the excretion of calcium through the kidneys.
• D. It stimulates the formation of new bone.

Correct answer: B

Rationale: The correct answer is B. Raloxifene, a selective estrogen receptor modulator (SERM), works by decreasing bone resorption and increasing bone density. This action helps in preventing osteoporosis by maintaining bone strength. Choice A is incorrect as raloxifene does not affect the absorption of calcium from the intestines. Choice C is incorrect as raloxifene does not increase the excretion of calcium through the kidneys. Choice D is incorrect as raloxifene does not directly stimulate the formation of new bone; instead, it primarily works by reducing bone loss.

4. Rhabdomyolysis can result in serious complications. In addition to muscle pain and weakness, a patient will complain of:

• A. paresthesias.
• B. bone pain.
• C. dark urine.
• D. diarrhea.

Correct answer: C

Rationale: Dark urine is a classic symptom of rhabdomyolysis. When muscle breakdown occurs, myoglobin is released into the bloodstream and filtered by the kidneys, leading to dark urine. Paresthesias (choice A) refer to abnormal sensations like tingling or numbness and are not typically associated with rhabdomyolysis. Bone pain (choice B) is not a prominent symptom of rhabdomyolysis. Diarrhea (choice D) is not a common complaint in rhabdomyolysis cases and is not directly related to muscle breakdown.

5. A male patient receiving androgen therapy is concerned about side effects. What is the most serious adverse effect the nurse should monitor for during this therapy?

• A. Increased risk of cardiovascular events
• B. Increased risk of bone fractures
• C. Increased risk of venous thromboembolism
• D. Increased risk of mood changes

Correct answer: A

Rationale: The correct answer is A: Increased risk of cardiovascular events. Androgen therapy can significantly increase the risk of cardiovascular events, such as heart attack and stroke, especially in older patients. Monitoring for signs and symptoms of cardiovascular issues is crucial during this therapy. Choice B, increased risk of bone fractures, is not typically associated with androgen therapy. Choice C, increased risk of venous thromboembolism, is more commonly linked to estrogen therapy rather than androgen therapy. Choice D, increased risk of mood changes, can occur with androgen therapy but is not as serious or life-threatening as cardiovascular events.

Similar Questions